Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced groundbreaking results from clinical trials of their drug, duvakitug, for ulcerative colitis and Crohn’s disease, two of the most prevalent forms of inflammatory bowel disease (IBD). The announcement, which sent Teva’s stock soaring by 26.4% to $20.88 and…
Indian automobile giant Tata Motors’ share price took a beating on Wednesday going down over 3% to hit an…
India’s benchmark indices Nifty 50 and Sensex started the day in the red on Tuesday. Nifty 50 sank below…
The JPMorgan Nasdaq Equity Premium ETF (JEPQ) and Nasdaq 100 Covered Call ETF (QYLD) funds offer some of the…
The JPMorgan Equity Premium Income ETF (JEPI) stock has had a strong performance this year as it jumped to…
CVS Health (CVS) stock price continued its strong downward trend as the company’s woes accelerated. Most recently, it has…
European markets started Tuesday on a weak note, with the pan-European Stoxx 600 index slipping 0.4% as all sectors…